Moclobemide treatment of resistant depression in a patient with vascular dementia

Yoram Barak*, Hanna Suholitsky, Shlomo Noy

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Patients suffering from dementia exhibit depressive symptoms in up to 86 per cent of cases. Syndromes meeting the criteria for major depression are more likely to respond to pharmacological therapy. Increased activity of MAO found in demented subjects make the treatment with MAO-inhibitors an obvious choice. Moclobemide is a novel reversible inhibitor of MAO. We describe a case of severe, resistant depression in a patient suffering from vascular dementia who responded rapidly to a low dose (150 mg/day) of moclobemide.

Original languageEnglish
Pages (from-to)67-68
Number of pages2
JournalHuman Psychopharmacology
Issue number1
StatePublished - Jan 1996
Externally publishedYes


  • Depression
  • Moclobemide
  • Vascular dementia


Dive into the research topics of 'Moclobemide treatment of resistant depression in a patient with vascular dementia'. Together they form a unique fingerprint.

Cite this